Accession Therapeutics Limited
Rejina Gurung has the following work experience:
- Associate Scientist at Accession Therapeutics Limited, starting from November 2022 to present.
- Associate Practitioner Microbiology at Basingstoke & North Hampshire Hospital, starting from November 2020 to December 2022.
- Shop Assistant/Trainer at Mooboo, starting from July 2018 to November 2020.
- ICT Apprentice at INTEGRATED GURKHA SECURITY SERVICES LIMITED, starting from September 2014 to August 2015.
Rejina Gurung's education history is as follows:
From 2019 to 2020, Rejina Gurung attended the University of Bath and completed a Master of Science degree in Molecular Bioscience.
Prior to that, from 2016 to 2019, Rejina Gurung studied at Coventry University and obtained a Bachelor of Science degree in Biomedical Sciences, with a focus on the general field of study.
Before attending university, from 2014 to 2016, Rejina Gurung attended The Bulmershe School and Sixth Form, although the degree name and field of study for this period are not specified.
Lastly, from 2011 to 2014, Rejina Gurung attended The Bulmershe School, however, the details regarding the degree obtained and field of study during this time are also not provided.
This person is not in any offices
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.